HDAC阻害剤のグローバル市場2023~2027:経口、非経口

【英語タイトル】Global HDAC Inhibitors Market 2023-2027

Technavioが出版した調査資料(IRTNTR72719-23)・商品コード:IRTNTR72719-23
・発行会社(調査会社):Technavio
・発行日:2023年1月25日
・ページ数:約120
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール(受注後24時間以内)
・調査対象地域:北米、ヨーロッパ、アジア太平洋、その他地域
・産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日〜2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・送付(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
❖ レポートの概要 ❖

Technavio社の本調査レポートによると、世界のHDAC阻害剤市場規模が2022年から2027年の間に172.61百万ドルに達すると予測されており、予測期間中に年平均7.73%成長すると見込まれます。本書ではHDAC阻害剤の世界市場について調査・分析し、エグゼクティブサマリー、市場状況、市場規模予測、過去の市場規模、ファイブフォース分析、投与経路別(経口、非経口)分析、流通チャネル別(病院薬局、小売薬局、オンライン薬局、その他)分析、顧客状況、地域別状況(北米、ヨーロッパ、アジア太平洋、その他地域、アメリカ、カナダ、イギリス、ドイツ、中国)分析、成長要因・課題・動向、企業状況、企業分析などの内容を掲載しています。なお、本書には、Acrotech Biopharma Inc., AstraZeneca Plc, Bio Techne Corp., BioVision Inc., Bristol Myers Squibb Co., Celleron Therapeutics Ltd., Curis Inc., Huya Bioscience International LLC, InvivoGen Corp., Italfarmaco Spa, Medivir AB, Merck and Co. Inc., Novartis AG, Onxeo SA, Shenzhen Chipscreen Biotechnology Co. Ltd., Syndax Pharmaceuticals Inc., Tokyo Chemical Industry Co. Ltd., Viracta Therapeutics Inc., Xynomic Pharmaceuticals (Nanjing) Co. Ltd., Cetya Therapeutics Inc.などの企業情報が含まれています。

・エグゼクティブサマリー
・市場状況
・市場規模予測
・過去の市場規模
・ファイブフォース分析

・世界のHDAC阻害剤市場規模:投与経路別
- 経口投与における市場規模
- 非経口投与における市場規模

・世界のHDAC阻害剤市場規模:流通チャネル別
- 病院薬局チャネルの市場規模
- 小売薬局チャネルの市場規模
- オンライン薬局チャネルの市場規模
- その他チャネルの市場規模

・地域別状況
- 北米のHDAC阻害剤市場規模
- ヨーロッパのHDAC阻害剤市場規模
- アジア太平洋のHDAC阻害剤市場規模
- その他地域のHDAC阻害剤市場規模
- アメリカのHDAC阻害剤市場規模
- カナダのHDAC阻害剤市場規模
- イギリスのHDAC阻害剤市場規模
- ドイツのHDAC阻害剤市場規模
- 中国のHDAC阻害剤市場規模

・成長要因・課題・動向
・企業状況
・企業分析

Technavio社は、利益、価格、競争、プロモーションなどの主要なパラメーターを分析することにより、また複数のソースからのデータを調査、統合、および合計することにより、市場の詳細な全体像を提示します。主要産業のインフルエンサーを特定することにより、さまざまな市場の側面を提示します。提示されたデータは包括的​​で信頼性が高く、一次および二次の広範な調査の結果です。Technavio社の市場調査レポートは、正確なHDAC阻害剤市場の成長を予測するための定性的および定量的調査を使用し、完全な競争状況と詳細なベンダー選択方法と分析を提供します。

HDAC阻害剤の世界市場 2023-2027

Technavio社は、HDAC阻害剤市場をモニターしており、2022年から2027年にかけて172.61百万ドルの成長が予測され、予測期間中のCAGRは7.73%で加速すると予測しています。当レポートでは、HDAC阻害剤市場について、市場規模や予測、動向、成長促進要因、課題などの全体的な分析に加え、約25のベンダーを網羅したベンダー分析も掲載しています。

当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。HDAC阻害剤市場は、高い標的親和性と特異性、がん領域における適応症の高い普及率、新規ドラッグデリバリーシステムと併用療法の開発によって牽引されています。

TechnavioのHDAC阻害剤市場は以下のように区分されています:

・投与経路別:
– 経口HDAC阻害剤
– 非経口HDAC阻害剤

・流通チャネル別:
– 病院薬局
– 小売薬局
– オンライン薬局
– その他

・地域別:
– 北米
– ヨーロッパ
– アジア
– その他の地域(ROW)

本調査では、今後数年間におけるHDAC阻害剤市場の成長を促進する主な理由の一つとして、高齢者人口の増加を挙げています。また、研究助成金や資金提供、癌に対する意識の高まりは、市場の大きな需要につながるでしょう。

Technavio社は、複数の情報源からのデータを調査、合成、要約し、主要パラメータの分析によって、市場の詳細な姿を提示します。

HDAC阻害剤市場に関する弊社の調査レポートは、以下の分野をカバーしています:
– HDAC阻害剤市場のサイジング
– HDAC阻害剤市場の予測
– HDAC阻害剤市場の産業分析

Technavio社の確実なベンダー分析は、クライアントが市場でのポジションを向上できるように設計されており、これに沿って本レポートには、Acrotech Biopharma Inc., AstraZeneca Plc, Bio Techne Corp., BioVision Inc., Bristol Myers Squibb Co., Celleron Therapeutics Ltd., Curis Inc., Huya Bioscience International LLC, InvivoGen Corp., Italfarmaco Spa, Medivir AB, Merck and Co. Inc., Novartis AG, Onxeo SA, Shenzhen Chipscreen Biotechnology Co. Ltd., Syndax Pharmaceuticals Inc., Tokyo Chemical Industry Co. Ltd., Viracta Therapeutics Inc., Xynomic Pharmaceuticals (Nanjing) Co. Ltd., and Cetya Therapeutics Incなどの企業情報が含まれています。また、HDAC阻害剤市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。本レポートでは、主要ベンダーの分析に加え、包括的な市場およびベンダーの状況を掲載しています。

Technavio社は、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細な姿を提示します。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示します。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。Technavioの市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market by Geography
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Route of Administration
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Distribution Channel
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2022
o 3.4 Market outlook: Forecast for 2022-2027
o Exhibit 14: Chart on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
• 4 Historic Market Size
o 4.1 Global HDAC (histone deacetylase) inhibitors market 2017 – 2021
o Exhibit 18: Historic Market Size – Data Table on Global HDAC (histone deacetylase) inhibitors market 2017 – 2021 ($ million)
o 4.2 Route of administration Segment Analysis 2017 – 2021
o Exhibit 19: Historic Market Size – Route of administration Segment 2017 – 2021 ($ million)
o 4.3 Distribution Channel Segment Analysis 2017 – 2021
o Exhibit 20: Historic Market Size – Distribution Channel Segment 2017 – 2021 ($ million)
o 4.4 Geography Segment Analysis 2017 – 2021
o Exhibit 21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
o 4.5 Country Segment Analysis 2017 – 2021
o Exhibit 22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2022 and 2027
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2022 and 2027
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2022 and 2027
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2022 and 2027
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2022 and 2027
• 6 Market Segmentation by Route of Administration
o 6.1 Market segments
o Exhibit 30: Chart on Route of Administration – Market share 2022-2027 (%)
o Exhibit 31: Data Table on Route of Administration – Market share 2022-2027 (%)
o 6.2 Comparison by Route of Administration
o Exhibit 32: Chart on Comparison by Route of Administration
o Exhibit 33: Data Table on Comparison by Route of Administration
o 6.3 Oral HDAC inhibitors – Market size and forecast 2022-2027
o Exhibit 34: Chart on Oral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 35: Data Table on Oral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 36: Chart on Oral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
o Exhibit 37: Data Table on Oral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
o 6.4 Parenteral HDAC inhibitors – Market size and forecast 2022-2027
o Exhibit 38: Chart on Parenteral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 39: Data Table on Parenteral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
o Exhibit 40: Chart on Parenteral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
o Exhibit 41: Data Table on Parenteral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
o 6.5 Market opportunity by Route of Administration
o Exhibit 42: Market opportunity by Route of Administration ($ million)
• 7 Market Segmentation by Distribution Channel
o 7.1 Market segments
o Exhibit 43: Chart on Distribution Channel – Market share 2022-2027 (%)
o Exhibit 44: Data Table on Distribution Channel – Market share 2022-2027 (%)
o 7.2 Comparison by Distribution Channel
o Exhibit 45: Chart on Comparison by Distribution Channel
o Exhibit 46: Data Table on Comparison by Distribution Channel
o 7.3 Hospital pharmacies – Market size and forecast 2022-2027
o Exhibit 47: Chart on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 48: Data Table on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 49: Chart on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 50: Data Table on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
o 7.4 Retail pharmacies – Market size and forecast 2022-2027
o Exhibit 51: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 52: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 53: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 54: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
o 7.5 Online pharmacies – Market size and forecast 2022-2027
o Exhibit 55: Chart on Online pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 56: Data Table on Online pharmacies – Market size and forecast 2022-2027 ($ million)
o Exhibit 57: Chart on Online pharmacies – Year-over-year growth 2022-2027 (%)
o Exhibit 58: Data Table on Online pharmacies – Year-over-year growth 2022-2027 (%)
o 7.6 Others – Market size and forecast 2022-2027
o Exhibit 59: Chart on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 60: Data Table on Others – Market size and forecast 2022-2027 ($ million)
o Exhibit 61: Chart on Others – Year-over-year growth 2022-2027 (%)
o Exhibit 62: Data Table on Others – Year-over-year growth 2022-2027 (%)
o 7.7 Market opportunity by Distribution Channel
o Exhibit 63: Market opportunity by Distribution Channel ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 65: Chart on Market share by geography 2022-2027 (%)
o Exhibit 66: Data Table on Market share by geography 2022-2027 (%)
o 9.2 Geographic comparison
o Exhibit 67: Chart on Geographic comparison
o Exhibit 68: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2022-2027
o Exhibit 69: Chart on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 70: Data Table on North America – Market size and forecast 2022-2027 ($ million)
o Exhibit 71: Chart on North America – Year-over-year growth 2022-2027 (%)
o Exhibit 72: Data Table on North America – Year-over-year growth 2022-2027 (%)
o 9.4 Europe – Market size and forecast 2022-2027
o Exhibit 73: Chart on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 74: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
o Exhibit 75: Chart on Europe – Year-over-year growth 2022-2027 (%)
o Exhibit 76: Data Table on Europe – Year-over-year growth 2022-2027 (%)
o 9.5 Asia – Market size and forecast 2022-2027
o Exhibit 77: Chart on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 78: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
o Exhibit 79: Chart on Asia – Year-over-year growth 2022-2027 (%)
o Exhibit 80: Data Table on Asia – Year-over-year growth 2022-2027 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2022-2027
o Exhibit 81: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 82: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
o Exhibit 83: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o Exhibit 84: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
o 9.7 US – Market size and forecast 2022-2027
o Exhibit 85: Chart on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 86: Data Table on US – Market size and forecast 2022-2027 ($ million)
o Exhibit 87: Chart on US – Year-over-year growth 2022-2027 (%)
o Exhibit 88: Data Table on US – Year-over-year growth 2022-2027 (%)
o 9.8 Canada – Market size and forecast 2022-2027
o Exhibit 89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
o Exhibit 91: Chart on Canada – Year-over-year growth 2022-2027 (%)
o Exhibit 92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
o 9.9 UK – Market size and forecast 2022-2027
o Exhibit 93: Chart on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
o Exhibit 95: Chart on UK – Year-over-year growth 2022-2027 (%)
o Exhibit 96: Data Table on UK – Year-over-year growth 2022-2027 (%)
o 9.10 Germany – Market size and forecast 2022-2027
o Exhibit 97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
o Exhibit 99: Chart on Germany – Year-over-year growth 2022-2027 (%)
o Exhibit 100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
o 9.11 China – Market size and forecast 2022-2027
o Exhibit 101: Chart on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 102: Data Table on China – Market size and forecast 2022-2027 ($ million)
o Exhibit 103: Chart on China – Year-over-year growth 2022-2027 (%)
o Exhibit 104: Data Table on China – Year-over-year growth 2022-2027 (%)
o 9.12 Market opportunity by geography
o Exhibit 105: Market opportunity by geography ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 106: Impact of drivers and challenges in 2022 and 2027
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 107: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 108: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 109: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 110: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 111: Matrix on vendor position and classification
o 12.3 Acrotech Biopharma Inc.
o Exhibit 112: Acrotech Biopharma Inc. – Overview
o Exhibit 113: Acrotech Biopharma Inc. – Product / Service
o Exhibit 114: Acrotech Biopharma Inc. – Key offerings
o 12.4 AstraZeneca Plc
o Exhibit 115: AstraZeneca Plc – Overview
o Exhibit 116: AstraZeneca Plc – Product / Service
o Exhibit 117: AstraZeneca Plc – Key news
o Exhibit 118: AstraZeneca Plc – Key offerings
o 12.5 Bristol Myers Squibb Co.
o Exhibit 119: Bristol Myers Squibb Co. – Overview
o Exhibit 120: Bristol Myers Squibb Co. – Product / Service
o Exhibit 121: Bristol Myers Squibb Co. – Key news
o Exhibit 122: Bristol Myers Squibb Co. – Key offerings
o 12.6 Celleron Therapeutics Ltd.
o Exhibit 123: Celleron Therapeutics Ltd. – Overview
o Exhibit 124: Celleron Therapeutics Ltd. – Key offerings
o 12.7 Curis Inc.
o Exhibit 125: Curis Inc. – Overview
o Exhibit 126: Curis Inc. – Product / Service
o Exhibit 127: Curis Inc. – Key offerings
o 12.8 Huya Bioscience International LLC
o Exhibit 128: Huya Bioscience International LLC – Overview
o Exhibit 129: Huya Bioscience International LLC – Product / Service
o Exhibit 130: Huya Bioscience International LLC – Key offerings
o 12.9 Italfarmaco Spa
o Exhibit 131: Italfarmaco Spa – Overview
o Exhibit 132: Italfarmaco Spa – Product / Service
o Exhibit 133: Italfarmaco Spa – Key offerings
o 12.10 Medivir AB
o Exhibit 134: Medivir AB – Overview
o Exhibit 135: Medivir AB – Product / Service
o Exhibit 136: Medivir AB – Key offerings
o 12.11 Merck and Co. Inc.
o Exhibit 137: Merck and Co. Inc. – Overview
o Exhibit 138: Merck and Co. Inc. – Business segments
o Exhibit 139: Merck and Co. Inc. – Key news
o Exhibit 140: Merck and Co. Inc. – Key offerings
o Exhibit 141: Merck and Co. Inc. – Segment focus
o 12.12 Novartis AG
o Exhibit 142: Novartis AG – Overview
o Exhibit 143: Novartis AG – Business segments
o Exhibit 144: Novartis AG – Key offerings
o Exhibit 145: Novartis AG – Segment focus
o 12.13 Onxeo SA
o Exhibit 146: Onxeo SA – Overview
o Exhibit 147: Onxeo SA – Product / Service
o Exhibit 148: Onxeo SA – Key offerings
o 12.14 Shenzhen Chipscreen Biotechnology Co. Ltd.
o Exhibit 149: Shenzhen Chipscreen Biotechnology Co. Ltd. – Overview
o Exhibit 150: Shenzhen Chipscreen Biotechnology Co. Ltd. – Product / Service
o Exhibit 151: Shenzhen Chipscreen Biotechnology Co. Ltd. – Key offerings
o 12.15 Syndax Pharmaceuticals Inc.
o Exhibit 152: Syndax Pharmaceuticals Inc. – Overview
o Exhibit 153: Syndax Pharmaceuticals Inc. – Key offerings
o 12.16 Viracta Therapeutics Inc.
o Exhibit 154: Viracta Therapeutics Inc. – Overview
o Exhibit 155: Viracta Therapeutics Inc. – Product / Service
o Exhibit 156: Viracta Therapeutics Inc. – Key offerings
o 12.17 Xynomic Pharmaceuticals (Nanjing) Co. Ltd.
o Exhibit 157: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – Overview
o Exhibit 158: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – Product / Service
o Exhibit 159: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 160: Inclusions checklist
o Exhibit 161: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 162: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 163: Research methodology
o Exhibit 164: Validation techniques employed for market sizing
o Exhibit 165: Information sources
o 13.5 List of abbreviations
o Exhibit 166: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market by Geography
Exhibits5: Executive Summary – Chart on Market Segmentation by Route of Administration
Exhibits6: Executive Summary – Chart on Market Segmentation by Distribution Channel
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2022-2027 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2022-2027 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2022-2027 (%)
Exhibits18: Historic Market Size – Data Table on Global HDAC (histone deacetylase) inhibitors market 2017 – 2021 ($ million)
Exhibits19: Historic Market Size – Route of administration Segment 2017 – 2021 ($ million)
Exhibits20: Historic Market Size – Distribution Channel Segment 2017 – 2021 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2017 – 2021 ($ million)
Exhibits22: Historic Market Size – Country Segment 2017 – 2021 ($ million)
Exhibits23: Five forces analysis – Comparison between 2022 and 2027
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2022 and 2027
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2022 and 2027
Exhibits26: Threat of new entrants – Impact of key factors in 2022 and 2027
Exhibits27: Threat of substitutes – Impact of key factors in 2022 and 2027
Exhibits28: Threat of rivalry – Impact of key factors in 2022 and 2027
Exhibits29: Chart on Market condition – Five forces 2022 and 2027
Exhibits30: Chart on Route of Administration – Market share 2022-2027 (%)
Exhibits31: Data Table on Route of Administration – Market share 2022-2027 (%)
Exhibits32: Chart on Comparison by Route of Administration
Exhibits33: Data Table on Comparison by Route of Administration
Exhibits34: Chart on Oral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits35: Data Table on Oral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits36: Chart on Oral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits37: Data Table on Oral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits38: Chart on Parenteral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits39: Data Table on Parenteral HDAC inhibitors – Market size and forecast 2022-2027 ($ million)
Exhibits40: Chart on Parenteral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits41: Data Table on Parenteral HDAC inhibitors – Year-over-year growth 2022-2027 (%)
Exhibits42: Market opportunity by Route of Administration ($ million)
Exhibits43: Chart on Distribution Channel – Market share 2022-2027 (%)
Exhibits44: Data Table on Distribution Channel – Market share 2022-2027 (%)
Exhibits45: Chart on Comparison by Distribution Channel
Exhibits46: Data Table on Comparison by Distribution Channel
Exhibits47: Chart on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits48: Data Table on Hospital pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits49: Chart on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits50: Data Table on Hospital pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits51: Chart on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits52: Data Table on Retail pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits53: Chart on Retail pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits54: Data Table on Retail pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits55: Chart on Online pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits56: Data Table on Online pharmacies – Market size and forecast 2022-2027 ($ million)
Exhibits57: Chart on Online pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits58: Data Table on Online pharmacies – Year-over-year growth 2022-2027 (%)
Exhibits59: Chart on Others – Market size and forecast 2022-2027 ($ million)
Exhibits60: Data Table on Others – Market size and forecast 2022-2027 ($ million)
Exhibits61: Chart on Others – Year-over-year growth 2022-2027 (%)
Exhibits62: Data Table on Others – Year-over-year growth 2022-2027 (%)
Exhibits63: Market opportunity by Distribution Channel ($ million)
Exhibits64: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits65: Chart on Market share by geography 2022-2027 (%)
Exhibits66: Data Table on Market share by geography 2022-2027 (%)
Exhibits67: Chart on Geographic comparison
Exhibits68: Data Table on Geographic comparison
Exhibits69: Chart on North America – Market size and forecast 2022-2027 ($ million)
Exhibits70: Data Table on North America – Market size and forecast 2022-2027 ($ million)
Exhibits71: Chart on North America – Year-over-year growth 2022-2027 (%)
Exhibits72: Data Table on North America – Year-over-year growth 2022-2027 (%)
Exhibits73: Chart on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits74: Data Table on Europe – Market size and forecast 2022-2027 ($ million)
Exhibits75: Chart on Europe – Year-over-year growth 2022-2027 (%)
Exhibits76: Data Table on Europe – Year-over-year growth 2022-2027 (%)
Exhibits77: Chart on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits78: Data Table on Asia – Market size and forecast 2022-2027 ($ million)
Exhibits79: Chart on Asia – Year-over-year growth 2022-2027 (%)
Exhibits80: Data Table on Asia – Year-over-year growth 2022-2027 (%)
Exhibits81: Chart on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits82: Data Table on Rest of World (ROW) – Market size and forecast 2022-2027 ($ million)
Exhibits83: Chart on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits84: Data Table on Rest of World (ROW) – Year-over-year growth 2022-2027 (%)
Exhibits85: Chart on US – Market size and forecast 2022-2027 ($ million)
Exhibits86: Data Table on US – Market size and forecast 2022-2027 ($ million)
Exhibits87: Chart on US – Year-over-year growth 2022-2027 (%)
Exhibits88: Data Table on US – Year-over-year growth 2022-2027 (%)
Exhibits89: Chart on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits90: Data Table on Canada – Market size and forecast 2022-2027 ($ million)
Exhibits91: Chart on Canada – Year-over-year growth 2022-2027 (%)
Exhibits92: Data Table on Canada – Year-over-year growth 2022-2027 (%)
Exhibits93: Chart on UK – Market size and forecast 2022-2027 ($ million)
Exhibits94: Data Table on UK – Market size and forecast 2022-2027 ($ million)
Exhibits95: Chart on UK – Year-over-year growth 2022-2027 (%)
Exhibits96: Data Table on UK – Year-over-year growth 2022-2027 (%)
Exhibits97: Chart on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits98: Data Table on Germany – Market size and forecast 2022-2027 ($ million)
Exhibits99: Chart on Germany – Year-over-year growth 2022-2027 (%)
Exhibits100: Data Table on Germany – Year-over-year growth 2022-2027 (%)
Exhibits101: Chart on China – Market size and forecast 2022-2027 ($ million)
Exhibits102: Data Table on China – Market size and forecast 2022-2027 ($ million)
Exhibits103: Chart on China – Year-over-year growth 2022-2027 (%)
Exhibits104: Data Table on China – Year-over-year growth 2022-2027 (%)
Exhibits105: Market opportunity by geography ($ million)
Exhibits106: Impact of drivers and challenges in 2022 and 2027
Exhibits107: Overview on Criticality of inputs and Factors of differentiation
Exhibits108: Overview on factors of disruption
Exhibits109: Impact of key risks on business
Exhibits110: Vendors covered
Exhibits111: Matrix on vendor position and classification
Exhibits112: Acrotech Biopharma Inc. – Overview
Exhibits113: Acrotech Biopharma Inc. – Product / Service
Exhibits114: Acrotech Biopharma Inc. – Key offerings
Exhibits115: AstraZeneca Plc – Overview
Exhibits116: AstraZeneca Plc – Product / Service
Exhibits117: AstraZeneca Plc – Key news
Exhibits118: AstraZeneca Plc – Key offerings
Exhibits119: Bristol Myers Squibb Co. – Overview
Exhibits120: Bristol Myers Squibb Co. – Product / Service
Exhibits121: Bristol Myers Squibb Co. – Key news
Exhibits122: Bristol Myers Squibb Co. – Key offerings
Exhibits123: Celleron Therapeutics Ltd. – Overview
Exhibits124: Celleron Therapeutics Ltd. – Key offerings
Exhibits125: Curis Inc. – Overview
Exhibits126: Curis Inc. – Product / Service
Exhibits127: Curis Inc. – Key offerings
Exhibits128: Huya Bioscience International LLC – Overview
Exhibits129: Huya Bioscience International LLC – Product / Service
Exhibits130: Huya Bioscience International LLC – Key offerings
Exhibits131: Italfarmaco Spa – Overview
Exhibits132: Italfarmaco Spa – Product / Service
Exhibits133: Italfarmaco Spa – Key offerings
Exhibits134: Medivir AB – Overview
Exhibits135: Medivir AB – Product / Service
Exhibits136: Medivir AB – Key offerings
Exhibits137: Merck and Co. Inc. – Overview
Exhibits138: Merck and Co. Inc. – Business segments
Exhibits139: Merck and Co. Inc. – Key news
Exhibits140: Merck and Co. Inc. – Key offerings
Exhibits141: Merck and Co. Inc. – Segment focus
Exhibits142: Novartis AG – Overview
Exhibits143: Novartis AG – Business segments
Exhibits144: Novartis AG – Key offerings
Exhibits145: Novartis AG – Segment focus
Exhibits146: Onxeo SA – Overview
Exhibits147: Onxeo SA – Product / Service
Exhibits148: Onxeo SA – Key offerings
Exhibits149: Shenzhen Chipscreen Biotechnology Co. Ltd. – Overview
Exhibits150: Shenzhen Chipscreen Biotechnology Co. Ltd. – Product / Service
Exhibits151: Shenzhen Chipscreen Biotechnology Co. Ltd. – Key offerings
Exhibits152: Syndax Pharmaceuticals Inc. – Overview
Exhibits153: Syndax Pharmaceuticals Inc. – Key offerings
Exhibits154: Viracta Therapeutics Inc. – Overview
Exhibits155: Viracta Therapeutics Inc. – Product / Service
Exhibits156: Viracta Therapeutics Inc. – Key offerings
Exhibits157: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – Overview
Exhibits158: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – Product / Service
Exhibits159: Xynomic Pharmaceuticals (Nanjing) Co. Ltd. – Key offerings
Exhibits160: Inclusions checklist
Exhibits161: Exclusions checklist
Exhibits162: Currency conversion rates for US$
Exhibits163: Research methodology
Exhibits164: Validation techniques employed for market sizing
Exhibits165: Information sources
Exhibits166: List of abbreviations



★調査レポート[HDAC阻害剤のグローバル市場2023~2027:経口、非経口] (コード:IRTNTR72719-23)販売に関する免責事項を必ずご確認ください。
★調査レポート[HDAC阻害剤のグローバル市場2023~2027:経口、非経口]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆